Close Menu

BMS

Without PGx-guided dosing information, it is unclear whether genetic testing to gauge Plavix response will go the same way as genetic testing for warfarin. At least one national insurer, Aetna, feels that the FDA did not provide enough information in the updated label to warrant coverage for the intervention.

At a March meeting with industry groups, the FDA gathered comments regarding the barriers to drug/diagnostic codevelopment and noted the agency might issue a series of white papers on the topic.

The company also released its fourth-quarter financial results, posting higher losses on increased research and development spending as it worked to move its first drug into the clinic this year.

The FDA has confirmed to DxS that its TheraScreen KRAS test is a Class III device. The company is in the process of submitting its premarket approval application to the agency.

The International Brotherhood of Electrical Workers launched its Stop Biotech Looting campaign last week after learning that subcontractors have been hiring non-union workers over the past year on a half-dozen projects for Boston-area life-sci giants.

The Massachusetts Life Sciences Center has approved spending a combined $2.5 million of the $1 billion, 10-year Life Sciences Act to subsidize life-sci companies that hire paid college-level interns, and to fund younger researchers.

Imperial College London and its spinout DNA Electronics have created a prototype for the so-called SNP Dr., which is being developed under a £1.2 million project that also includes Pfizer.

NHLBI plans to launch next month the prospectively designed, randomized-controlled study, called Clarification of Optimal Anticoagulation through Genetics trial, which will follow 1,200 patients to see if PGx-guided dosing is clinically useful.

Top executives last week from Alexandria Real Estate Equities, BioMed Realty Trust, and HCP said life-sci shops are increasingly skittish about leasing new space for the long term, leading the REITs to reduce spending on construction and renovation projects this year.

Without specific guidance from the FDA regarding KRAS testing, drugmakers Bristol-Myers Squibb and Amgen are facing lower sales of their colorectal cancer drugs Erbitux and Vectibix, and may need to get creative in how they market their drugs to patients and doctors.

Pages

Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.

University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.

NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.

In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.